Gilead Opens 182,000-Square-Foot Research Center, Advancing $32 Billion U.S. R&D and Manufacturing Investment

Gilead Sciences查看公司主页 has opened a 182,000-square-foot Research Center at its Foster City, California headquarters, expanding its capabilities in oncology, inflammation, and research data science to advance medicines for some of the world's most challenging diseases. The milestone, marked with a ribbon-cutting ceremony attended by company leaders, scientists, and government and community guests, is a key component of Gilead's planned $32 billion investment in U.S. research, development, and manufacturing through 2030.

"We are in a moment of unprecedented opportunity in science and technology. Our new Research Center will help Gilead scientists make the most of that opportunity, delivering more breakthrough medicines faster," said Daniel O'Day, Chairman and Chief Executive Officer, Gilead Sciences查看公司主页. "As part of our broader $32 billion investment in the United States, this new facility also reflects our long-term commitment to American innovation."

A Hub for Discovery Across Key Therapeutic Areas

The new Research Center builds on Gilead's longstanding presence in California. Today, Gilead employs approximately 11,000 people across the United States, including more than 7,400 in California and nearly 4,700 in the Bay Area. The five-story center will support approximately 325 employees, including 260 laboratory scientists.

Designed with input from Gilead research colleagues, the facility features flexible laboratory neighborhoods, specialized collaboration spaces, and shared technology platforms intended to enable teams to adapt as scientific needs evolve. "The future of biomedical innovation depends on bringing together exceptional science, advanced technologies and diverse expertise," said Flavius Martin, MD, Executive Vice President, Research, Gilead Sciences查看公司主页. "This center was designed to do exactly that. By co-locating key research disciplines and expanding our data science capabilities, we are strengthening the infrastructure needed to accelerate discovery and advance meaningful innovations."

A dedicated bridge to an adjacent building streamlines the transfer of equipment and research materials, while a new Research Quad provides a central gathering space for collaboration and scientific exchange.

Part of a Broader U.S. Investment Strategy

The Research Center is one of three major Foster City projects advancing Gilead's broader U.S. investment in research, development, and manufacturing through 2030. The Technical Development Center, expected to open in 2027, and the biologics facility, which broke ground in August and is expected to open in 2029, will further strengthen Gilead's U.S. research and development infrastructure.

The biologics facility, known as the Chess biologics facility, will strengthen Gilead's end-to-end biologics capabilities, providing greater scale, speed, and flexibility to support the development of innovative medicines from clinical development through commercial launch. It is estimated to be completed by 2029.

Sustainability and Regional Impact

The Research Center incorporates all-electric systems, energy-efficient design, and water-saving landscaping featuring California native plants, which are expected to support LEED Gold certification.

"Foster City is home to some of the most important biomedical research happening anywhere in the world, and Gilead's continued investment here is a vote of confidence in California's life sciences workforce," said Kevin Mullin, U.S. Representative for California's 15th Congressional District. "The new center expands Gilead's research capacity in Foster City, supporting the region's biotechnology leadership and skilled workforce."

"San Mateo County is one of the most important and vital biotechnology centers in the world," said Diane Papan, California State Assemblymember, 21st District. "Gilead's sustained support for science, infrastructure and skilled jobs only strengthens our position."